Picture courtesy PTI
New Delhi: Bharat Biotech on Friday received approval from the Drugs Controller General of India (DCGI) to conduct its intranasal COVID-19 booster dose trials in India.
The trials are likely to be conducted at nine locations across the country, on 900 individuals.
The Subject Expert Committee (SEC) had earlier given in-principle approval for phase III booster dose study of Bharat Biotech’s intranasal COVID vaccine.
The Hyderabad-based pharmaceutical firm had proposed an intranasal booster dose for those who have been administered two doses of Covaxin or Covishield.
Prime Minister Narendra Modi had said last month that India will soon have an indigenous nasal COVID vaccine.
India launched a ‘precautionary’ third dose for frontline workers and senior citizens earlier this month.
Also Read: Intranasal COVID-19 Vaccine More Effective Than Traditional Counterparts
Bhubaneswar: The Railway Protection Force (RPF) seized more than 100 turtles while being transported in…
Berhampur: In order to help the college and university teachers in their research activities in…
New Delhi: The Congress party on Tuesday released another list of candidates for the ongoing…
New Delhi: A former Miss Ecuador contestant was shot and killed by two gunmen in…
Bhubaneswar: Another former MLA of BJD in Odisha resigned from the party on Tuesday after…
New Delhi: AstraZeneca's startling revelation about the rare side effects of their Covishield vaccine has…
Bhubaneswar: Odisha's Khandapada MLA Soumya Ranjan Patnaik on Tuesday said the BJP had proposed him…
Bhubaneswar: Day temperature crossed 46 degree Celsius in Odisha with Bhubaneswar recording its hottest day…